Benjamin Saylor

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

Pembrolizumab plus olaparib may improve prostate-specific antigen response rate in patients with metastatic castration-resistant prostate cancer regardless of homologous recombination repair mutation status.

Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.

Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.

Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.

Pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiotherapy appears to be a promising and efficacious, bladder-sparing regimen for patients with muscle-invasive bladder cancer.

The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.

The activity and safety of investigational combinations will be subject to study in patients with advanced clear cell renal cell carcinoma (ccRCC) as part of a phase 1b/2 umbrella platform trial.

February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.

February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.

Neither monotherapy with durvalumab or combination treatment with durvalumab plus tremelimumab met co-primary end points of overall survival vs chemotherapy for the treatment of metastatic urothelial cancer.

The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.